EyePoint completes enrollment in Phase 3 DURAVYU diabetic macular edema trials COMO, CAPRI

• EyePoint completed enrollment in two Phase 3 trials of DURAVYU for diabetic macular edema, enrolling over 480 patients in five months.
• Topline 56-week results have not been presented; the readout is expected in 4Q 2027.
• The studies aim to show DURAVYU can match standard care while reducing how often patients need treatment.
• A safety committee review in May 2026 supported continuing the Phase 3 programs without changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300700PRIMZONEFULLFEED9800587) on July 30, 2026, and is solely responsible for the information contained therein.